Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Predicting the risk of serious muscle disorders in individuals eligible for statin treatment in England: derivation and validation of a clinical prediction model.

The Lancet. Digital health·2026
Same author

Diagnostic Implications of Multi-Cancer Early Detection Testing in the Investigation of Cancer Symptoms: An Exploratory Retrospective Analysis of the SYMPLIFY Study.

The Lancet regional health. Europe·2026
Same author

Economic Evaluation of Oral Nirmatrelvir-Ritonavir for COVID-19 in Higher Risk Outpatients.

JAMA network open·2026
Same author

Nirmatrelvir-ritonavir versus usual care in at-risk adults with early SARS-CoV-2 infection in the UK, 2022-23: virological and immunological results of an open-label randomised trial (PANORAMIC).

The Lancet. Microbe·2026
Same author

Oral Nirmatrelvir-Ritonavir for Covid-19 in Higher-Risk Outpatients.

The New England journal of medicine·2026
Same author

Differentiating the COVID-19 Infection and Vaccine Experiences of Patients With Systemic, Single Organ, and Overlap Immune-Mediated Inflammatory Disease: Protocol for a Secondary Analysis for Enhancing COVID-19 Vaccine Pharmacovigilance.

JMIR research protocols·2026

Related Experiment Videos

Statins in heart failure: retrospective cohort study using routine primary care data.

Ronan P Ryan1, Richard J McManus, Jonathan Mant

  • 1Primary Care Clinical Sciences, Primary Care Clinical Sciences Building, University of Birmingham, Birmingham B15 2TT, UK.

Annals of Medicine
|June 13, 2009
PubMed
Summary

Statin use before a heart failure diagnosis was associated with a significantly lower risk of death. These findings suggest that primary care physicians should continue statin prescriptions for patients diagnosed with heart failure.

Related Experiment Videos

Area of Science:

  • Cardiology
  • Primary Care Medicine
  • Pharmacology

Background:

  • Statins are widely prescribed in primary care, but their benefit in heart failure (HF) is debated.
  • Many patients receive statins before an HF diagnosis.
  • The impact of pre-diagnosis statin use on HF survival is not well understood.

Purpose of the Study:

  • To evaluate the effect of statin prescription before a heart failure diagnosis on survival in incident HF patients.
  • To inform clinical practice regarding statin use in patients who develop heart failure.

Main Methods:

  • Retrospective cohort study using UK primary care electronic records (1995-2004).
  • Identified 10,914 incident heart failure cases.
  • Used Cox regression to analyze the association between pre-diagnosis statin use and 2-year mortality.

Main Results:

  • 20% of HF patients (2185/10,914) were prescribed statins prior to diagnosis.
  • Pre-diagnosis statin use was associated with a 48% lower risk of death within 2 years (HR 0.52; 95% CI 0.39-0.68), after adjusting for confounders.
  • Only 2% of patients initiated statin therapy after HF diagnosis.

Conclusions:

  • Patients prescribed statins before a heart failure diagnosis appear to benefit from continued use, likely due to effects on cardiovascular comorbidities.
  • Discontinuation of pre-diagnosis statin therapy at the time of HF diagnosis is not recommended.
  • Statin therapy may play a beneficial role in managing patients with underlying cardiovascular conditions that can lead to heart failure.